WHO 498 Classification of Tumours of Haematopoietic and Lymphoid Tissues, 2008. ,
Distinct types of diffuse large B-cell lymphoma identified by gene expression
profiling, Nature, vol.303, issue.6769, pp.503-514, 2000. ,
DOI : 10.1038/35000501
A gene expression- 504 based method to diagnose clinically distinct subgroups of diffuse large B cell 505 lymphoma, Proceedings of the National Academy of Sciences of the United States of 506 ,
The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile, Blood, vol.99, issue.7, pp.2285-90, 2002. ,
DOI : 10.1182/blood.V99.7.2285
PTEN loss 511 defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B- 512 cell lymphoma, Proceedings of the National Academy of Sciences of the United States 513 of America, pp.12420-12425, 2013. ,
Molecular 515 subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways, 516 Proceedings of the National Academy of Sciences of the United States of America, pp.13520-13525, 2008. ,
Aggressive lymphomas. The New England journal of medicine, pp.1417-1446, 2010. ,
The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma, Blood, vol.102, issue.12, pp.3871-80, 2003. ,
DOI : 10.1182/blood-2003-06-1841
Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells, Blood, vol.125, issue.7, pp.1061-73, 2015. ,
DOI : 10.1182/blood-2014-11-610436
Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium, Blood, vol.117, issue.26, pp.7070-529, 2011. ,
DOI : 10.1182/blood-2011-04-345256
Accurate 531 Classification of Germinal Center B-Cell-Like/Activated B-Cell-Like Diffuse Large B, p.532 ,
536 Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined 537 by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. 538 Journal of clinical oncology : official journal of the American Society of Clinical 539 Oncology, pp.2848-56, 2015. ,
Discovery 541 and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by 542 whole-exome sequencing, Proceedings of the National Academy of Sciences of the 543 United States of America, pp.3879-84, 2012. ,
Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing, Blood, vol.122, issue.7, pp.1256-65, 2013. ,
DOI : 10.1182/blood-2013-02-483727
Genome sequencing of lymphoid malignancies. Blood. American 548 Society of Hematology, pp.3899-907, 2013. ,
Somatic 550 mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of 551 germinal-center origin. Nature genetics, pp.181-186, 2010. ,
553 Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma, Nature, vol.554476, pp.298-303, 2011. ,
Oncogenically 556 active MYD88 mutations in human lymphoma, Nature, vol.557470, pp.115-124, 2011. ,
DOI : 10.1038/nature09671
Analysis of 559 the coding genome of diffuse large B-cell lymphoma. Nature genetics. Nature 560 Publishing Group, pp.830-837, 2011. ,
Genetic heterogeneity of diffuse large B-cell lymphoma, 562 Proceedings of the National Academy of Sciences, pp.1398-403, 2013. ,
DOI : 10.1073/pnas.1205299110
The molecular pathogenesis of primary mediastinal large B-cell lymphoma, Blood, vol.118, issue.10, pp.2659-69, 2011. ,
DOI : 10.1182/blood-2011-05-326538
Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma, Blood, vol.114, issue.6, pp.1236-1278, 2009. ,
DOI : 10.1182/blood-2009-03-209759
URL : https://hal.archives-ouvertes.fr/inserm-00411059
Recurrent targets of aberrant somatic hypermutation in lymphoma, Oncotarget, vol.3, issue.11, pp.1308-1327, 2012. ,
DOI : 10.18632/oncotarget.653
571 Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next 572 ,
Exploiting 595 synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer cell, pp.723-760, 2012. ,
PIM 598 kinases are progression markers and emerging therapeutic targets in diffuse large B-cell 599 lymphoma. British journal of cancer, pp.491-500, 2012. ,
DOI : 10.1038/bjc.2012.272
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405213
BCL2 601 mutations in diffuse large B-cell lymphoma. Leukemia, pp.20121383-90 ,
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study, Blood, vol.120, issue.19, pp.3986-97, 2012. ,
DOI : 10.1182/blood-2012-05-433334
Burkitt 608 lymphoma pathogenesis and therapeutic targets from structural and functional 609 genomics, Nature. Nature Publishing Group, vol.490, pp.116-136, 2012. ,
DOI : 10.1038/nature11378
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609867
The 611 diagnostic gray zone between Burkitt lymphoma and diffuse large B-cell lymphoma is 612 also a gray zone of the mutational spectrum, Leukemia, p.613, 2015. ,
TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and 615 primary mediastinal B cell lymphoma. The Journal of experimental medicine, pp.616981-616990, 2009. ,
Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation, Oncogene, vol.28, issue.18, pp.2679-84, 2006. ,
DOI : 10.1038/sj.onc.1209151
MHC class II 624 transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers, Nature, vol.625471, pp.377-81, 2011. ,
DOI : 10.1038/nature09754
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902849
Inositol 1,3,4,5-tetrakisphosphate controls proapoptotic Bim gene expression and survival in B cells, Proceedings of the National Academy of Sciences, vol.104, issue.35, pp.13978-83, 2007. ,
DOI : 10.1073/pnas.0704312104
MASL1, a candidate oncogene found in amplification at 8p23.1, is translocated in immunoblastic B-cell lymphoma cell line OCI-LY8, Oncogene, vol.23, issue.14, pp.2576-81, 2004. ,
DOI : 10.1038/sj.onc.1207352
SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients, Leukemia, vol.98, issue.1, pp.108-125, 2014. ,
DOI : 10.1038/leu.2013.263
Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia, Blood, vol.120, issue.23, pp.4621-4655, 2012. ,
DOI : 10.1182/blood-2012-05-429506
The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age, Haematologica, vol.96, issue.12, pp.1888-90, 2011. ,
DOI : 10.3324/haematol.2011.050617
Dose- 642 adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. The New 643 England journal of medicine, pp.1408-1424, 2013. ,
DOI : 10.1056/nejmoa1214561
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568999
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial, The Lancet, vol.378, issue.9806, pp.1858-67, 2011. ,
DOI : 10.1016/S0140-6736(11)61040-4
Analysis of FOXO1 mutations in diffuse large B-cell lymphoma, Blood, vol.121, issue.18, pp.3666-74, 2013. ,
DOI : 10.1182/blood-2013-01-479865
MYD88 (L265P) mutation is an independent prognostic factor for 652 outcome in patients with diffuse large B-cell lymphoma. Leukemia. Nature Publishing 653 Group, pp.2104-2110, 2014. ,
655 Somatic mutations of cell-free circulating DNA detected by Next Generation 656 Sequencing reflect the genetic changes in both Germinal Center B-Cell like and 657 ,
Cell like Diffuse Large B-Cell Lymphoma tumors at the time of diagnosis, Haematologica. Haematologica, vol.658, 2015. ,